Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network

Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network

Background: This study aims at describing the therapeutic outcome of patients carrying the R92Q variant in the TNFRSF1A gene treated with anakinra (ANA) or canakinumab (CAN) and identifying any factors predictive of complete response to IL-1 inhibition. Methods: Clinical data of patients treated wit...

Full description

Bibliographic Details
Main Authors: Carla Gaggiano, Donato Rigante, José Hernández-Rodríguez, Antonio Vitale, Maria Tarsia, Alessandra Soriano, Giuseppe Lopalco, Florenzo Iannone, Masen Abdel Jaber, Roberto Giacomelli, Ewa Wiȩsik-Szewczyk, Marco Cattalini, Micol Frassi, Matteo Piga, Gaafar Ragab, Jurgen Sota, Fiammetta Zunica, Alberto Floris, Vito Sabato, Mohamed Tharwat Hegazy, Olga Araújo, Laura Pelegrín, Alessandra Fabbiani, Alessandra Renieri, Salvatore Grosso, Claudia Fabiani, Bruno Frediani, Luca Cantarini
Format: Article
Language:English
Published: SAGE Publishing 2021-08-01
Series:Therapeutic Advances in Musculoskeletal Disease
Online Access:https://doi.org/10.1177/1759720X211037178

Internet

https://doi.org/10.1177/1759720X211037178

Similar Items